Teragen Bio Obtains Patent for Infectious Disease Vaccine Development Technology

Patent Related to Immunowon Prediction Algorithm

[Asia Economy Reporter Kim Ji-hee] Theragen Bio announced on the 9th that it has obtained a patent for an epitope prediction algorithm, a core technology for developing vaccines against new infectious diseases such as COVID-19.

This patent is for a "Method and computer program for epitope prediction for virus treatment." It is an artificial intelligence (AI) technology that predicts nucleotide sequence regions optimized for immune formation in the body by analyzing immunogenicity and binding affinity based on viral genome data.

The method predicts the binding affinity between HLA (human leukocyte antigen) allele sequences, which can determine immunogenicity and tissue compatibility of the subject, obtained from virus-derived peptide (amino acid chain) sequences, and based on this, infers immunity after binding to generate optimal viral antigen information.

A Theragen Bio official stated, "With this patented technology, vaccine models for various viruses can be designed," and added, "We are considering commercialization through the use of our own genome analysis technology and partnerships with domestic and international contract development and manufacturing organizations (CDMOs)."

Theragen Bio possesses a viral genome RNA (ribonucleic acid) analysis system using NGS (next-generation sequencing). Accordingly, through this patent, the company has simultaneously acquired its own sequencing capability and AI-based infectious disease vaccine development capability.

This content was produced with the assistance of AI translation services.